Abstract
The use of oral antiplatelet therapy in reducing vascular events has been extensively studied. Currently available oral antiplatelet agents include aspirin and the thienopyridine P2Y12 receptor antagonists. These classes are combined frequently in the setting of acute coronary syndrome and percutaneous coronary intervention (PCI). Resistance to either or both of these agents is a major concern, as antiplatelet resistance has been linked to an increase in thrombotic events and worse clinical outcomes. As a result, there is a need for newer, more effective antiplatelet agents to address the limitations of currently available therapy. Prasugrel, a third generation thienopyridine, has been approved by both the FDA and European Commission. Two additional P2Y12 agents, ticagrelor and cangrelor are in advanced stages of development. The possible advantages of prasugrel over clopidogrel include a faster onset of action, reduced inter-patient variability and more potent platelet inhibition. Ticagrelor is an oral reversible P2Y12 antagonist with greater platelet inhibition compared with clopidogrel. Cangrelor is being developed as an intravenous P2Y12 antagonist with a very fast onset and offset, which may offer advantages particularly in the setting of coronary intervention. These emerging antiplatelet agents may offer advantages such as faster onset of action, greater potency and reversibility of platelet inhibition. This article summarizes the available clinical data on the upcoming P2Y12 antiplatelet agents in the treatment of coronary artery disease.
Keywords: P2Y12 receptor antagonists, prasugrel, ticagrelor, cangrelor
Current Vascular Pharmacology
Title: Emerging P2Y12 Receptor Antagonists: Role in Coronary Artery Disease
Volume: 8 Issue: 1
Author(s): Carrie S. Oliphant, J. Bradford Doby, Crystal L. Blade, Kanak Das, Debabrata Mukherjee and Pranab Das
Affiliation:
Keywords: P2Y12 receptor antagonists, prasugrel, ticagrelor, cangrelor
Abstract: The use of oral antiplatelet therapy in reducing vascular events has been extensively studied. Currently available oral antiplatelet agents include aspirin and the thienopyridine P2Y12 receptor antagonists. These classes are combined frequently in the setting of acute coronary syndrome and percutaneous coronary intervention (PCI). Resistance to either or both of these agents is a major concern, as antiplatelet resistance has been linked to an increase in thrombotic events and worse clinical outcomes. As a result, there is a need for newer, more effective antiplatelet agents to address the limitations of currently available therapy. Prasugrel, a third generation thienopyridine, has been approved by both the FDA and European Commission. Two additional P2Y12 agents, ticagrelor and cangrelor are in advanced stages of development. The possible advantages of prasugrel over clopidogrel include a faster onset of action, reduced inter-patient variability and more potent platelet inhibition. Ticagrelor is an oral reversible P2Y12 antagonist with greater platelet inhibition compared with clopidogrel. Cangrelor is being developed as an intravenous P2Y12 antagonist with a very fast onset and offset, which may offer advantages particularly in the setting of coronary intervention. These emerging antiplatelet agents may offer advantages such as faster onset of action, greater potency and reversibility of platelet inhibition. This article summarizes the available clinical data on the upcoming P2Y12 antiplatelet agents in the treatment of coronary artery disease.
Export Options
About this article
Cite this article as:
Oliphant S. Carrie, Doby Bradford J., Blade L. Crystal, Das Kanak, Mukherjee Debabrata and Das Pranab, Emerging P2Y12 Receptor Antagonists: Role in Coronary Artery Disease, Current Vascular Pharmacology 2010; 8 (1) . https://dx.doi.org/10.2174/157016110790226615
DOI https://dx.doi.org/10.2174/157016110790226615 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biochemical Aspects of Nitric Oxide
Current Pharmaceutical Design Nitric Oxide and Teratogenesis: An Update
Current Pharmaceutical Design Inhibition of Drug Efflux in Mycobacteria with Phenothiazines and Other Putative Efflux Inhibitors
Recent Patents on Anti-Infective Drug Discovery Herpes Simplex Virus-Induced Ocular Diseases: Detrimental Interaction Between Virus and Host
Current Immunology Reviews (Discontinued) Potential Role of Rho-Associated Protein Kinase Inhibitors for Glaucoma Treatment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Cardiovascular Effects of EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibodies
Cardiovascular & Hematological Agents in Medicinal Chemistry TRYCAT Pathways Link Peripheral Inflammation, Nicotine, Somatization and Depression in the Etiology and Course of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Contrast Medium Induced Nephropathy: New Insights into Prevention and Risk Management
Cardiovascular & Hematological Agents in Medicinal Chemistry Drug Discovery and Design for Complex Diseases through QSAR Computational Methods
Current Pharmaceutical Design NO-NSAIDs: From Inflammatory Mediators to Clinical Readouts
Inflammation & Allergy - Drug Targets (Discontinued) Leptin Signaling in Blood Platelets as a Target for Therapeutic Intervention
Current Signal Transduction Therapy Ligands of Diltiazem Binding Site: An Overview of Some Chemotypes
Mini-Reviews in Medicinal Chemistry Bacterial Toxins: Potential Weapons Against HIV Infection
Current Pharmaceutical Design Safety and Efficacy of Melatonin in Pediatric Migraine Prophylaxis
Current Drug Safety Quassinoids: From Traditional Drugs to New Cancer Therapeutics
Current Medicinal Chemistry Controlled and Continuous Release Ocular Drug Delivery Systems: Pros and Cons
Current Drug Delivery Synaptic Inputs of Neural Afferent Pathways to Vasopressin- and Oxytocin-Secreting Neurons of Supraoptic and Paraventricular Hypothalamic Nuclei
Endocrine, Metabolic & Immune Disorders - Drug Targets Simple and Efficient Synthesis of Novel bis-Betti Bases via a One-Pot Pseudo-Five-Component Reaction
Letters in Organic Chemistry Circadian Rhythm in Cytokines Administration
Mini-Reviews in Medicinal Chemistry Aryltetralin-type Lignan of Podophyllum: A Comprehensive Review
The Natural Products Journal